Acne Vulgaris
Conditions
Keywords
clindamycin, tretinoin, acne vulgaris, Acne vulgaris mild to moderate
Brief summary
The purpose of this study is to determine the safety and efficacy of association between tretinoin and clindamycin phosphate on the treatment of acne vulgaris mild and moderate.
Interventions
DRUGapplication of the topic gel
Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
Sponsors
Igefarma Laboratorios S.A.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Individuals of both sexes with age greater than or equal to 12 years * Subjects diagnosed with acne vulgaris in the face, except for the nasal area, range from mild to moderate, with the following requirements. * Mild acne = presence of fewer than 20 comedones or less than 15 lesions, inflammatory lesions or a total of less than 30 injuries. * Moderate acne = presence of 20 the 100 comedones or of 15 the 50 inflamatory lesions or a total of 30 the 125 lesions, with not more than lesions small nodule until 5,0 mm. * Ensure that the existing injuries were not submitted any treatment for acne, topical or systemic, within the last 30 days. * Be able to properly follow the determinations of the Protocol. * Has provided a written voluntary consent to participate in the study, by signing the informed consent, before being subjected to any procedure. * Under 18 years old, be accompanied by legal guardian in the process of obtaining the informed consent. * Be mentally able to provide consent and be fulfilling all the requirements of the study.
Exclusion criteria
* Pregnant women or in periods of lactation. * Women of childbearing age and sexual activity with not using safe contraceptive method, such as oral contraceptives, implantable, injectable or intra-uterine, introduced for at least 120 days. * Women who are using oral contraceptives containing the hormone combination for acetate ciprosterone and etinolestradiol, association of drospirenone and ethinyl estradiol, or desogestrel. * Clinical evidence or history of immunodeficiency. * Any use of immunosuppressive drug and/or immunomodulating over the past 3 months, topical or systemic. * Concurrent use of fotossentetizadores, neuromuscular blockers, medications that exacerbate the acne, blockers (filters) with solar alcoholic vehicle, spironolactone, flutamide or zinc salts. * Prior use of systemic retinoid. * Presence of acne medication and/or cosmetic. * History of systemic metabolic disorder that can interfere with the integrity of the skin. * History of inflammatory disease, intestinal or regional enteritis and/or symptoms similar. * History of joy to any of the components of the formula (active principle or carrier). * History of abuse of alcohol and/or illegal drugs. * History of non-adherence to medical treatment earlier. * Any clinical observation made by the investigator that prohibits participation in the study of the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the efficacy, through number of lesions, and tolerability of the product. | three months |
Countries
Brazil
Outcome results
None listed